Study Endpoints:
Patients were established to be under CR if they had an M1 marrow i.e.,
<5% blasts by bone marrow aspirate subsequent to second-line
salvage induction therapy, without evidence of circulating blasts or
extra-medullary disease and peripheral count recovery defined as ANC
(absolute neutrophil count) > 0.75 x 10 9/L and Plt (platelet) count > 75 x 10 9/L. Patients who did not attain a CR subsequent to salvage induction
therapy were determined to have induction failure. Successive relapses
amongst patients who were in CR were pathologically defined confirmed as
M3 marrow i.e., ≥ 25 % leukemic blasts or presence of extra-medullary
disease. Overall survival duration of the cohort for disease-recurrence
was determined from relapse date to date last seen and in case of a
deceased patient date of demise was used , while overall survival of
cohort for diagnosis was determined form diagnosis date to date last
seen or date of demise in case of a deceased patient.